Imiglucerase
Orphan Drug Cold Chain RequiredFDA Approved
Contents
Description
Imiglucerase is a recombinant DNA-derived form of the human enzyme acid beta-glucosidase. It is used as enzyme replacement therapy for patients with Gaucher disease.
Indications & Therapeutic Use
Gaucher's disease type I, Gaucher's disease type III
Linked Diseases:
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| Registered | — | 5 days | Commercially available | |
| — | — | — | — |
Buy / Source Imiglucerase — GNH India
10 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Imiglucerase products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Imiglucerase
| Generic Name | Imiglucerase |
| Brands | 1 brand available |
| Active Ingredient | Imiglucerase |
| Drug Class | Gaucher's disease type I |
| Manufacturer | Sanofi Genzyme |
| Dosage Forms | IV infusion, 200 units/vial, 400 units/vial |
| Medical Code | A16AB02 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes